{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:10:18Z","timestamp":1781712618180,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-00979-w","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T07:02:28Z","timestamp":1727766148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4291-6223","authenticated-orcid":false,"given":"Praveen","family":"Neeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry Ayn Mayson A.","family":"Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafei","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xen Ping","family":"Hoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith Syson","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-1714","authenticated-orcid":false,"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"979_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Prim. 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"979_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"979_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle, R. A. et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 378, 241\u2013249 (2018).","journal-title":"N. Engl. J. Med."},{"key":"979_CR4","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362\u20131369 (2006).","journal-title":"N. Engl. J. Med."},{"key":"979_CR5","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"979_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle, R. A. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346, 564\u2013569 (2002).","journal-title":"N. Engl. J. Med."},{"key":"979_CR7","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).","journal-title":"Sci. Transl. Med."},{"key":"979_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847 (2017).","journal-title":"N. Engl. J. Med."},{"key":"979_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13046-022-02421-2","volume":"41","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Expanding anti-CD38 immunotherapy for lymphoid malignancies. J. Exp. Clin. Cancer Res. 41, 210 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"979_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"979_CR11","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali, S. A. et al. T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688\u20131700 (2016).","journal-title":"Blood"},{"key":"979_CR12","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N. et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267\u20132280 (2018).","journal-title":"J. Clin. Oncol."},{"key":"979_CR13","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent, S. A. et al. \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat. Commun. 6, 7333 (2015).","journal-title":"Nat. Commun."},{"key":"979_CR14","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N. et al. T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267\u20132280 (2018).","journal-title":"J. Clin. Oncol."},{"key":"979_CR15","first-page":"505","volume":"130","author":"AD Cohen","year":"2017","unstructured":"Cohen, A. D. et al. Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM). Blood 130, 505 (2017).","journal-title":"Blood"},{"key":"979_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med."},{"key":"979_CR17","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406\u20132410 (2016).","journal-title":"Blood"},{"key":"979_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.bi.56.070187.003151","volume":"56","author":"AG Gilman","year":"1987","unstructured":"Gilman, A. G. G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem. 56, 615\u2013649 (1987).","journal-title":"Annu. Rev. Biochem."},{"key":"979_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1124\/mol.117.111062","volume":"93","author":"K Sriram","year":"2018","unstructured":"Sriram, K. & Insel, P. A. G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol. Pharm. 93, 251\u2013258 (2018).","journal-title":"Mol. Pharm."},{"key":"979_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/d41573-023-00064-2","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard, A. Setting GPCRs free. Nat. Rev. Drug Discov. 22, 347\u2013348 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"979_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith, E. L. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 11, eaau7746 (2019).","journal-title":"Sci. Transl. Med."},{"key":"979_CR22","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti, K. et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 135, 1232\u20131243 (2020).","journal-title":"Blood"},{"key":"979_CR23","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij, C. P. M. et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 5, 2196\u20132215 (2021).","journal-title":"Blood Adv."},{"key":"979_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/17474086.2021.1909469","volume":"14","author":"M Braunstein","year":"2021","unstructured":"Braunstein, M., Weltz, J. & Davies, F. A new decade: novel immunotherapies on the horizon for relapsed\/refractory multiple myeloma. Expert Rev. Hematol. 14, 377\u2013389 (2021).","journal-title":"Expert Rev. Hematol."},{"key":"979_CR25","doi-asserted-by":"crossref","unstructured":"Moreau, P. & Touzeau, C. T-cell redirecting bispecific antibodies in multiple myeloma: a revolution? Blood 139, 3681\u20133687 (2022).","DOI":"10.1182\/blood.2021014611"},{"key":"979_CR26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4049\/jimmunol.122.2.609","volume":"122","author":"J Radl","year":"1979","unstructured":"Radl, J., De Glopper, E. D., Schuit, H. R. & Zurcher, C. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL\/KaLwRij mice. J. Immunol. 122, 609\u2013613 (1979).","journal-title":"J. Immunol."},{"key":"979_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S8756-3282(97)00056-2","volume":"20","author":"IR Garrett","year":"1997","unstructured":"Garrett, I. R., Dallas, S., Radl, J. & Mundy, G. R. A murine model of human myeloma bone disease. Bone 20, 515\u2013520 (1997).","journal-title":"Bone"},{"key":"979_CR28","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.omtn.2023.04.003","volume":"32","author":"JA Williams","year":"2023","unstructured":"Williams, J. A. & Paez, P. A. Improving cell and gene therapy safety and performance using next-generation nanoplasmid vectors. Mol. Ther. Nucleic Acids 32, 494\u2013503 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"979_CR29","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan, A. J. et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 4, 1221\u20131227 (2018).","journal-title":"JAMA Oncol."},{"key":"979_CR30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","volume":"42","author":"J Atamaniuk","year":"2012","unstructured":"Atamaniuk, J. et al. Overexpression of G protein\u2010coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur. J. Clin. Invest. 42, 953\u2013960 (2012).","journal-title":"Eur. J. Clin. Invest."},{"key":"979_CR31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","volume":"18","author":"Y Cohen","year":"2013","unstructured":"Cohen, Y., Gutwein, O., Garach-Jehoshua, O., Bar-Haim, A. & Kornberg, A. GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology 18, 348\u2013351 (2013).","journal-title":"Hematology"},{"key":"979_CR32","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","volume":"18","author":"T Kodama","year":"2019","unstructured":"Kodama, T. et al. Anti-GPRC5D\/CD3 bispecific T-cell\u2013redirecting antibody for the treatment of multiple myeloma. Mol. Cancer Ther. 18, 1555\u20131564 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"979_CR33","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody, S. et al. GPRC5D-targeted CAR T cells for myeloma. N. Engl. J. Med. 387, 1196\u20131206 (2022).","journal-title":"N. Engl. J. Med."},{"key":"979_CR34","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1158\/1538-7445.AM2022-6020","volume":"82","author":"W Huang","year":"2022","unstructured":"Huang, W. et al. Abstract 6020: Preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma. Cancer Res. 82, 6020\u20136020 (2022).","journal-title":"Cancer Res."},{"key":"979_CR35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med."},{"key":"979_CR36","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A. et al. Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387, 2232\u20132244 (2022).","journal-title":"N. Engl. J. Med."},{"key":"979_CR37","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1128\/JVI.01250-10","volume":"85","author":"JM Luke","year":"2011","unstructured":"Luke, J. M. et al. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J. Virol. 85, 1370\u20131383 (2011).","journal-title":"J. Virol."},{"key":"979_CR38","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1126\/science.273.5273.352","volume":"273","author":"Y Sato","year":"1996","unstructured":"Sato, Y. et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273, 352\u2013354 (1996).","journal-title":"Science"},{"key":"979_CR39","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.4049\/jimmunol.158.8.3635","volume":"158","author":"DM Klinman","year":"1997","unstructured":"Klinman, D. M., Yamshchikov, G. & Ishigatsubo, Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 158, 3635\u20133639 (1997).","journal-title":"J. Immunol."},{"key":"979_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","volume":"23","author":"NY Sardesai","year":"2011","unstructured":"Sardesai, N. Y. & Weiner, D. B. Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol. 23, 421\u2013429 (2011).","journal-title":"Curr. Opin. Immunol."},{"key":"979_CR41","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1128\/JVI.02564-07","volume":"82","author":"J Liu","year":"2008","unstructured":"Liu, J., Kjeken, R., Mathiesen, I. & Barouch, D. H. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J. Virol. 82, 5643\u20135649 (2008).","journal-title":"J. Virol."},{"key":"979_CR42","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.4049\/jimmunol.179.7.4741","volume":"179","author":"G Ahl\u00e9n","year":"2007","unstructured":"Ahl\u00e9n, G. et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3\/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J. Immunol. 179, 4741\u20134753 (2007).","journal-title":"J. Immunol."},{"key":"979_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107120","volume":"26","author":"P Neeli","year":"2023","unstructured":"Neeli, P. et al. Comparison of DNA vaccines with AS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2. iScience 26, 107120 (2023).","journal-title":"iScience"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00979-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00979-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00979-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T08:03:25Z","timestamp":1727769805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00979-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["979"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-00979-w","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}